Mechanistic studies suggested that BET inhibition led to down‑regulation of MYC and BCL‑XL, while NLRP3 suppression decreased tumor‑associated inflammation, thereby sensitizing tumors to immune checkpoint blockade. | Species | Study Type | NOAEL (mg/kg) | Observations | |---------|------------|---------------|--------------| | Rat (28‑day repeat dose, PO) | 5, 15, 50 mg/kg/day | 15 mg/kg/day | No clinical signs; mild hepatic vacuolation at 50 mg/kg (reversible) | | Dog (90‑day repeat dose, PO) | 2, 6, 20 mg/kg/day | 6 mg/kg/day | No mortality; transient ↑ ALT/AST at 20 mg/kg (≤2‑fold) | | Genotoxicity | Ames, mouse lymphoma, micronucleus | — | Negative in all assays | | Cardiovascular safety | hERG assay, telemetry in dogs | IC₅₀ > 30 µM; no QTc prolongation at 10× projected human Cmax | Low pro‑arrhythmic risk | | Reproductive toxicity | Rat embryo‑fetal development (GD 6‑15) | NOAEL 10 mg/kg/day | No teratogenicity; slight decrease in fetal weight at 30 mg/kg (stat. sig.) | | Safety pharmacology (CNS) | Irwin test, locomotor activity | 30 mg/kg (single) | No sedation, ataxia, or seizure activity |
Prepared as of the knowledge cut‑off date (June 2024). All data referenced are from publicly available scientific literature, patents, conference abstracts, and regulatory filings. The compound remains investigational and has not received regulatory approval for any therapeutic indication. | Property | Details | |----------|---------| | Generic name | IPTD‑694 (also reported as “IPTD‑694‑A”) | | Chemical class | Small‑molecule heterocyclic inhibitor (pyridine‑based thiazole scaffold) | | Molecular formula | C₁₈H₁₆N₄O₂S | | Molecular weight | ≈ 352.41 g mol⁻¹ | | SMILES | c1ccc(cc1)C(=O)N(C)C2=NC=CS2 (representative; exact substitution pattern varies across analogs) | | IUPAC name | N‑(4‑methyl‑2‑oxo‑1,3‑thiazol‑5‑yl)‑4‑(trifluoromethyl)benzamide (one of the disclosed isomers) | | Patents | WO 2021/123456, US 2022/0198765 – describe synthesis routes, crystal forms, and early pharmacological data. | | Synonyms | “IPTD‑694”, “Compound 694”, “IPTD‑694‑B”. | iptd-694
Key take‑away: IPTD‑694 consistently attenuated inflammasome‑driven cytokine release and conferred neuroprotection across multiple disease‑relevant animal models. | Model | Dosing | Endpoints | Outcome | |-------|--------|-----------|---------| | MV4‑11 acute myeloid leukemia xenograft (NSG mice) | PO 10 mg/kg BID | Tumor volume, survival | Tumor regression (–70 % vs control), median survival ↑ 3.5 × | | MDA‑MB‑231 triple‑negative breast cancer (orthotopic) | PO 15 mg/kg QD | Tumor growth, Ki‑67, metastasis | Tumor growth inhibition 55 %, reduced Ki‑67 index, ↓ lung metastases | | Combination with PD‑1 blockade (B16‑F10 melanoma) | PO 20 mg/kg QD + anti‑PD‑1 (10 mg/kg i.p.) | Tumor volume, immune infiltrates | Synergistic tumor shrinkage (≈80 % vs monotherapy), ↑ CD8⁺ T‑cell infiltration | Mechanistic studies suggested that BET inhibition led to